Menu Search
Equities

Mercator Medical SA

MM2:FRA

Mercator Medical SA

Actions
  • Price (EUR)12.10
  • Today's Change0.000 / 0.00%
  • Shares traded60.00
  • 1 Year change+37.42%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Mercator Medical SA had revenues fall -13.54% from 542.51m to 469.06m, though the company grew net income from a loss of 189.62m to a smaller loss of 19.68m.
Gross margin7.85%
Net profit margin-0.92%
Operating margin-9.90%
Return on assets-0.46%
Return on equity-0.28%
Return on investment-0.50%
More ▼

Cash flow in PLNView more

In 2023, Mercator Medical SA did not generate a significant amount of cash. However, Cash Flow from Investing totalled 33.59m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 86.00k for operations while cash used for financing totalled 41.07m.
Cash flow per share2.21
Price/Cash flow per share29.19
Book value per share86.83
Tangible book value per share83.50
More ▼

Balance sheet in PLNView more

Mercator Medical SA appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio7.01
Quick ratio5.57
Total debt/total equity0.006
Total debt/total capital0.006
More ▼

Growth rates in PLN

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		103.82
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.